[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma

[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma

2026.02.03
For patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) at high postoperative risk, the standard of adjuvant concurrent chemoradiotherapy (CRT) has remained unchanged since 2004—despite persistent rates of recurrence and metastasis. Recently, the NIVOPOST-OP trial, led by Yungang Tao of Gustave Roussy Cancer Center, was published in The Lancet, delivering the first definitive breakthrough in nearly 20 years.
Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

2026.02.03
On January 28, a landmark study was published in the world-leading medical journal The BMJ. For the first time, a multicenter randomized controlled trial (RCT) has demonstrated that the reliability of urological telesurgery is non-inferior to conventional local robotic surgery.
Professor Jiwei Huang: Clinical Challenges and Future Perspectives of Neoadjuvant Therapy in Renal Cell Carcinoma丨Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology

Professor Jiwei Huang: Clinical Challenges and Future Perspectives of Neoadjuvant Therapy in Renal Cell Carcinoma丨Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology

2026.02.03
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together leading experts and young scholars in the field of urologic oncology, aiming to establish a high-level academic exchange platform and to jointly explore frontier topics and unresolved challenges in the diagnosis and treatment of urologic malignancies.
From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

2026.02.03
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together the emerging backbone of China’s urologic oncology community, aiming to promote standardized and innovative development in the diagnosis and treatment of urologic malignancies through cutting-edge academic discussion and clinical experience sharing.
CASH 2026 | Professor Zhijian Xiao: Precision Risk Stratification and Emerging Therapeutic Advances in MDS

CASH 2026 | Professor Zhijian Xiao: Precision Risk Stratification and Emerging Therapeutic Advances in MDS

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health priorities. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Zhijian Xiao from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into recent advances in precision risk stratification for myelodysplastic syndromes (MDS) and emerging targeted and immunotherapeutic strategies, highlighting the growing clinical importance of molecular classification in treatment decision-making.
CASH 2026 | Professor Hui Wei: Frontiers in Precision Therapy for AML and New Management Pathways for High-Risk Patients

CASH 2026 | Professor Hui Wei: Frontiers in Precision Therapy for AML and New Management Pathways for High-Risk Patients

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health strategies. During the conference, Oncology Frontier – Hematology Frontier invited Professor Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into breakthroughs in FLT3 and IDH1/2 targeted therapy, precision strategies for elderly and high-risk AML populations, and MRD-guided dynamic treatment approaches, offering valuable perspectives for clinical practice and translational research.
CASH 2026 | Professor Lanping Xu: Advances and Optimization Strategies in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

CASH 2026 | Professor Lanping Xu: Advances and Optimization Strategies in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to discuss cutting-edge advances in hematology and national health priorities. During the conference, Oncology Frontier – Hematology Frontier invited Professor Lanping Xu from Peking University People’s Hospital to share her team’s latest progress in hematopoietic stem cell transplantation (HSCT) for severe aplastic anemia (SAA), with a focus on long-term outcomes of haploidentical transplantation, as well as optimization of transplant timing, patient stratification, and donor selection.
CASH 2026 | Professor Zimin Sun: Current Applications, Core Advantages, and Future Prospects of Umbilical Cord Blood Transplantation

CASH 2026 | Professor Zimin Sun: Current Applications, Core Advantages, and Future Prospects of Umbilical Cord Blood Transplantation

2026.02.01
As an emerging modality of hematopoietic stem cell transplantation, umbilical cord blood transplantation (UCBT) has demonstrated unique clinical value in the treatment of various hematologic diseases. From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading hematology experts from China and abroad to explore cutting-edge research and national health priorities. During the conference, Professor Zimin Sun from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, shared in-depth insights into the current clinical status, technical advantages, and evolving research landscape of UCBT.
Annual Review | Professor Wei Xu: New Trends and Future Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)

Annual Review | Professor Wei Xu: New Trends and Future Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)

2026.02.01
From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the meeting, Professor Wei Xu from Jiangsu Provincial People’s Hospital provided a comprehensive review of key advances in CLL treatment, therapeutic decision-making in high-risk disease, and future research directions, offering valuable insights for optimizing clinical practice.
Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer

Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer

2026.01.31
HER2-positive breast cancer was once associated with aggressive behavior and poor prognosis. However, with the rapid advancement of targeted therapies—particularly antibody–drug conjugates (ADCs)—this subtype has evolved into a highly treatable and potentially curable disease. In 2025, landmark studies across neoadjuvant, adjuvant, and metastatic settings have reshaped treatment paradigms toward greater precision and individualization. During the 2025 Yixian Breast Cancer Conference and CSCO BC South Forum, Oncology Frontier interviewed Professor Chang Gong from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, who summarized the most impactful annual advances in HER2-positive breast cancer treatment.